For patients living with breast cancer and diabetes, choosing the right medication matters. A large analysis of routine medical records shows that semaglutide is linked to better survival outcomes compared to other common diabetes drugs like metformin or SGLT2 inhibitors. This finding comes from a review of data spanning nearly 29 million patients, offering a rare look at real-world results outside of strict clinical trials.
The study followed over 4,800 patients with pre-existing breast cancer for 24 months. Those taking semaglutide experienced a much lower mortality rate, with only 54 deaths among users versus 395 deaths among those on other medications. The data also showed that fewer people on semaglutide developed metastatic disease, which is cancer that has spread to other parts of the body. Even when comparing semaglutide directly to tirzepatide, a newer drug in the same class, survival rates were similar, though the difference was not statistically significant in this specific comparison.
It is important to remember that this was an observational study, meaning it shows an association rather than proving that the drug causes these benefits. While the results are promising and suggest a potential advantage for semaglutide, doctors need to run controlled trials to confirm these findings. These results motivate further research into how these medications might help breast cancer patients across different stages and treatment settings.